A randomised study to compare intravenous granisetron versus ondensetron on hemodynamics sensory and motor block after spinal anaesthesia with hyperbaric bupivacaine in patients undergoing lower segment caesarean section - NIL

开始日期2024-11-25

申办/合作机构

SMS Medical College & Hospital

CTRI/2024/10/075611

/ Not yet recruitingN/AIIT

Comparison of efficacy of ondansetron and granisetron in prevention of postoperative nausea and vomiting in middle ear surgeries: a prospective randomised double-blind study - nil

开始日期2024-10-29

申办/合作机构-

CTRI/2024/09/073695

/ Not yet recruitingN/AIIT

A comparative study of clinical efficacy of pretreatment between intravenous Granisetron and intravenous Lignocaine to allaevate pain on Propofol injection during general anaesthesia. - NIL

开始日期2024-09-23

申办/合作机构-

100 项与格拉司琼相关的临床结果

登录后查看更多信息

100 项与格拉司琼相关的转化医学

登录后查看更多信息

100 项与格拉司琼相关的专利（医药）

登录后查看更多信息

1,614

项与格拉司琼相关的文献（医药）

2024-11-01·Bulletin of Experimental Biology and Medicine

Features of Stress-Induced Changes in Heart Rate Variability During Blockade of Central and Stimulation of Peripheral Serotonin and Dopamine Receptors in Rats

Article

作者: Kuryanova, E V ; Stupin, V O ; Tryasuchev, A V

The dynamics of heart rate variability (HRV) during acute stress was studied in male nonlinear rats that received single injection of serotonin (200 μg/kg) or dopamine (60 μg/kg), regular (4-fold) injections of central serotonin receptor blockers (ketanserin and granisetron, 0.1 mg/kg each) or central dopamine receptor blockers (0.1 mg/kg SCH-23390 and 10 mg/kg sulpiride), as well as a combination of central receptor blockers with the administration of serotonin or dopamine, respectively. During stress against the background of serotonin receptors blockade, a weak tachycardia, low stress index, high rhythm variability, especially in the low-frequency range were recorded; against the background of dopamine receptors blockade, increased reactivity to stress at high HR, an initial increase in the stress index, and a decrease in rhythm variability, followed by an increase in the proportion of very low frequency waves in the spectrum were revealed. Serotonin and dopamine, by stimulating peripheral receptors, predominantly weakened stress-induced changes in HRV (especially serotonin), but in combination with blockade of the corresponding central receptors contributed to maintaining tachycardia, reduced rhythm variability, and potentiated the effects of blockers in relation to stress induced changes in the wave structure of the HRV spectrum. We believe that central and peripheral serotoninergic and dopaminergic structures are involved in the formation of HRV by modulating the activity of components of the autonomous and central circuits of HR regulation, respectively.

2024-11-01·Journal of Surgical Research

Transcutaneous Pericardium 6 Acupoint Electrical Stimulation Provides Comparable Antiemetic Effect to Granisetron When Combined With Dexamethasone in Patients Undergoing Breast Cancer Surgery

Article

作者: Yang, Li ; Luo, Lu ; Zhang, Jun ; Lou, Feifei

INTRODUCTIONPerioperative transcutaneous pericardium 6 (P6) electrical stimulation is effective for prevention of postoperative nausea and vomiting (PONV). The patients undergoing breast cancer surgery have a high PONV prevalence; however, the effectiveness of P6 stimulation in this surgical population has not been investigated.MATERIALS AND METHODSA total of 198 patients undergoing mastectomy under general anesthesia were enrolled. They were randomly assigned to the one of three treatments: P6 stimulation + dexamethasone (group PD, n = 66), granisetron + dexamethasone (group GD, n = 66), and dexamethasone alone (group DM, n = 66). The primary endpoint was the incidence of postoperative vomiting (POV) within postoperative 48h. The secondary endpoints included the use of rescue antiemetic, severity of POV, and the incidence of postoperative nausea and other adverse events.RESULTSThe incidence of POV in group PD (9.1%) was similar to group GD (10.6%, P = 0.770), but significantly lower than that in the group DM (28.8%, P = 0.004) within postoperative 48 h. And, the incidence of postoperative nausea was similar between group PD and group GD but lower than that in group DM. The use of rescue antiemetics had no statistical differences among the three groups. The median (interquartile range) scores of POV severity were higher in group GD [6.0 (5.0, 7.0)] than in group DM [4.0 (3.0, 6.0), P = 0.012] within postoperative 48 h, but similar to group PD [5.5 (4.0, 6.3), P = 0.208].CONCLUSIONSCombined with dexamethasone, P6 stimulation has similar effectiveness for PONV prophylaxis with 5- hydroxytryptamine 3 antagonist granisetron but lower cost of antiemetic use. Moreover, both groups had a lower incidence of PONV and higher satisfaction than dexamethasone alone in patients undergoing breast cancer surgery.

2024-09-18·BMC biotechnology

Anti-inflammatory potential of aspergillus unguis SP51-EGY: TLR4-dependent effects & chemical diversity via Q-TOF LC-HRMS.

Article

作者: Fayad, Walid ; Ibrahim, Amal Mosad ; Abdelnaser, Anwar ; El-Hady, Faten K Abd ; Dawood, Abdelhameed S ; Abdel-Aziz, Mohamed S ; Nasr, Soad

Inflammation serves as an intricate defense mechanism for tissue repair. However, overactivation of TLR4-mediated inflammation by lipopolysaccharide (LPS) can lead to detrimental outcomes such as sepsis, acute lung injury, and chronic inflammation, often associated with cancer and autoimmune diseases. This study delves into the anti-inflammatory properties of "Aspergillus unguis isolate SP51-EGY" on LPS-stimulated RAW 264.7 macrophages. Through real-time qPCR, we assessed the expression levels of pivotal inflammatory genes, including iNOS, COX-2, TNF-α, and IL-6. Remarkably, our fungal extracts significantly diminished NO production and showed noteworthy reductions in the mRNA expression levels of the aforementioned genes. Furthermore, while Nrf2 is typically associated with modulating inflammatory responses, our findings indicate that the anti-inflammatory effects of our extracts are not Nrf2-dependent. Moreover, the chemical diversity of the potent extract (B Sh F) was elucidated using Q-TOF LC-HRMS, identifying 54 compounds, some of which played vital roles in suppressing inflammation. Most notably, compounds like granisetron, fenofibrate, and umbelliprenin were found to downregulate TNF-α, IL-1β, and IL-6 through the NF-κB signaling pathway. In conclusion, "Aspergillus unguis isolate SP51-EGY", isolated from the Red Sea, Egypt, has been unveiled as a promising TLR4 inhibitor with significant anti-inflammatory potentials, presenting novel insights for their potential therapeutic use in inflammation.

项与格拉司琼相关的新闻（医药）

2024-12-23

·药筛

布比卡因脂质体仿制不批准，久安肾上腺素注射液（预充式）上市申请 | 仿制药周报（12.16-12.22）

统计每周仿制药一致性评价申报、上市申请（12.16-12.22） 1、仿制药上市申请获批药品名称企业名称类型受理号氨溴特罗口服溶液海门普适医药有限公司3CYHS2302491布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2403649布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2403648复合磷酸氢钾注射液仁合益康汇泽药业河北有限公司;河北仁合益康药业有限公司3CYHS2400682黄体酮注射液北京布霖生物科技有限公司;华夏生生药业（北京）有限公司3CYHS2301078黄体酮注射液华夏生生药业（北京）有限公司3CYHS2301003甲硝唑凝胶江苏晨牌邦德药业有限公司4CYHS2301950硝普钠注射液南京泽恒医药技术开发有限公司;天津金耀药业有限公司3CYHS2301878盐酸环喷托酯滴眼液沈阳兴齐眼药股份有限公司4CYHS2303317盐酸肾上腺素注射液马鞍山丰原制药有限公司3CYHS2400756乙酰半胱氨酸注射液合肥国药诺和药业有限公司;国药集团国瑞药业有限公司3CYHS2400493乙酰半胱氨酸注射液福安药业集团庆余堂制药有限公司3CYHS2301671 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称类型醋酸泼尼松片安徽金太阳生化药业有限公司CYHB2450402甲硝唑片湖北省宏源药业科技股份有限公司;湖北同德堂药业有限公司CYHB2350652聚普瑞锌颗粒吉林省博大伟业制药有限公司CYHB2350908硫酸阿米卡星注射液浙江诚意药业股份有限公司CYHB2350563尼可地尔片天方药业有限公司CYHB2450242维生素B6片山西亨瑞达制药有限公司CYHB2150625盐酸丁螺环酮片北大医药股份有限公司CYHB2350812盐酸丁螺环酮片北大医药股份有限公司CYHB2350813盐酸二甲双胍肠溶胶囊北京圣永制药有限公司CYHB2350790盐酸二甲双胍肠溶胶囊北京圣永制药有限公司CYHB2350789盐酸伐昔洛韦片湖北广济药业股份有限公司CYHB2450037注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350895注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350897注射用哌拉西林钠他唑巴坦钠海口奇力制药股份有限公司CYHB2350896注射用头孢哌酮钠舒巴坦钠(2:1)广东金城金素制药有限公司CYHB2350849注射用头孢哌酮钠舒巴坦钠(2:1)广东金城金素制药有限公司CYHB2350848注射用头孢他啶苏州二叶制药有限公司CYHB2350861注射用头孢他啶苏州二叶制药有限公司CYHB2350860注射用头孢他啶苏州二叶制药有限公司CYHB2350859注射用头孢西丁钠浙江惠迪森药业有限公司CYHB2350845注射用头孢西丁钠浙江惠迪森药业有限公司CYHB2350846 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称类型受理号阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404441阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404443他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404459甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404454枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404446枸橼酸氢钾钠颗粒成都恒瑞制药有限公司4CYHS2404449盐酸伐昔洛韦片浙江车头制药股份有限公司;杭州领业医药科技有限公司4CYHS2404440他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404458碘[131I]化钠口服溶液广东君奇医药科技有限公司3CYHS2404438玻璃酸钠滴眼液江苏福邦药业有限公司4CYHS2404460阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404444维生素B6注射液江西远超医药科技有限公司;朗天药业（湖北）有限公司3CYHS2404453他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404457注射用硫酸艾沙康唑湖南科伦制药有限公司4CYHS2404461甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404455比索洛尔氨氯地平片江苏德源药业股份有限公司4CYHS2404456枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404448甲磺酸沙非胺片石家庄四药有限公司4CYHS2404435恩他卡朋双多巴片（Ⅱ）浙江京新药业股份有限公司4CYHS2404442重酒石酸去甲肾上腺素注射液山西普恒制药有限公司3CYHS2404450枸橼酸西地那非片广东培杰药物研究有限公司;江苏永安制药有限公司4CYHS2404447双氯芬酸钠肠溶片四川天德制药有限公司4CYHS2404451复合磷酸氢钾注射液内蒙古白医制药股份有限公司3CYHS2404445依折麦布阿托伐他汀钙片（II）重庆圣华曦药业股份有限公司4CYHS2404452丁溴东莨菪碱注射液广东博卓医药科技有限公司;烟台鲁银药业有限公司4CYHS2404439盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司;石家庄科仁医药科技有限公司3CYHS2404428注射用乳糖酸红霉素广东态森德制药有限公司;广东星昊药业有限公司3CYHS2404422盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司;石家庄科仁医药科技有限公司3CYHS2404429双氯芬酸依泊胺贴杭州端本医药科技有限公司;南京海纳制药有限公司3CYHS2404427尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404430注射用磷酸特地唑胺吉林津升制药有限公司4CYHS2404420美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404425甲磺酸沙非胺片石家庄四药有限公司4CYHS2404436美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404426盐酸氮卓斯汀滴眼液江西马应龙美康药业有限公司;浙江尖峰药业有限公司4CYHS2404424注射用氟氧头孢钠四川制药制剂有限公司;浙江惠迪森药业有限公司4CYHS2404423盐酸尼卡地平注射液江西东抚制药有限公司4CYHS2404434甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404431甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404432尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404433盐酸赛庚啶口服溶液苏州华健瑞达医药技术有限公司;浙江京新药业股份有限公司3CYHS2404421苯磺贝他斯汀口崩片漯河市汇创医药有限公司;裕松源药业有限公司3CYHS2404404非奈利酮片天地恒一制药股份有限公司4CYHS2404406重酒石酸去甲肾上腺素注射液浙江尚科生物医药有限公司3CYHS2404416富马酸伏诺拉生片重庆世森医药科技有限公司;烟台鲁银药业有限公司4CYHS2404409比索洛尔氨氯地平片浙江百代医药科技有限公司;浙江赛默制药有限公司4CYHS2404419硫酸镁注射液江苏润恒制药有限公司3CYHS2404413卡泊三醇搽剂福元药业有限公司4CYHS2404415钆特醇注射液河北仁合益康药业有限公司4CYHS2404414环索奈德吸入气雾剂上海上药信谊药厂有限公司3CYHS2404405头孢克肟颗粒广东华南药业集团有限公司;金鸿药业股份有限公司3CYHS2404410倍他米松磷酸钠注射液河南利华制药有限公司;河南润弘制药股份有限公司3CYHS2404411吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司;江苏大红鹰恒顺药业有限公司3CYHS2404418硫酸镁注射液江苏润恒制药有限公司3CYHS2404412富马酸伏诺拉生片重庆世森医药科技有限公司;烟台鲁银药业有限公司4CYHS2404408布美他尼注射液云南华派医药科技有限公司;楚雄和创药业有限责任公司3CYHS2404407吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司;江苏大红鹰恒顺药业有限公司3CYHS2404417盐酸布比卡因注射液湖北津药药业股份有限公司3CYHS2404387阿昔莫司胶囊河北锐健医药科技有限公司;淄博万杰制药有限公司4CYHS2404391聚乙二醇4000散（儿童型）郑州泰丰制药有限公司3CYHS2404390熊去氧胆酸片中山百灵生物技术股份有限公司;安士制药（中山）有限公司3CYHS2404398小儿法罗培南钠颗粒广东九明制药有限公司4CYHS2404389阿贝西利片齐鲁制药有限公司4CYHS2404403盐酸奥洛他定滴眼液武汉新瑞医药科技有限公司;武汉五景药业有限公司4CYHS2404399盐酸尼卡地平注射液浙江花园药业有限公司4CYHS2404394培哚普利氨氯地平片（III）浙江华海药业股份有限公司4CYHS2404395夫西地酸乳膏西藏奥斯必秀医药有限公司;浙江康恩贝制药股份有限公司4CYHS2404386阿贝西利片齐鲁制药有限公司4CYHS2404402苯磺酸氨氯地平口服溶液四川奥邦古得药业有限公司;南京海纳制药有限公司3CYHS2404396盐酸伐地那非口崩片哈尔滨三联药业股份有限公司3CYHS2404392异氟烷福建海西联合药业有限公司4CYHS2404388盐酸丙卡特罗颗粒四川大冢制药有限公司3CYHS2404400格拉司琼透皮贴片杭州朱养心药业有限公司4CYHS2404393阿贝西利片齐鲁制药有限公司4CYHS2404401硫酸羟氯喹片珠海润都制药股份有限公司4CYHS2404397氢溴酸替格列汀片常州千红生化制药股份有限公司4CYHS2404378达格列净二甲双胍缓释片（Ⅰ）南通联亚药业股份有限公司4CYHS2404362替米沙坦氨氯地平片江苏百佑药业有限公司;山东丰金生物医药有限公司4CYHS2404374托吡酯片山东新时代药业有限公司4CYHS2404365阿托伐他汀钙片浙江江北药业有限公司4CYHS2404379吸入用盐酸丙卡特罗溶液石家庄四药有限公司3CYHS2404384夫西地酸乳膏广东科泓药业有限公司4CYHS2404370醋酸特利加压素注射液武汉华龙生物制药有限公司3CYHS2404363恩格列净二甲双胍缓释片山东力诺制药有限公司;重庆博腾药业有限公司3CYHS2404372肾上腺素注射液（预充式）武汉久安药物研究院有限公司;武汉久安药业有限公司3CYHS2404369硫代硫酸钠注射液赤峰源生药业有限公司3CYHS2404371氧氟沙星滴耳液江苏宝东医药科技有限公司;知和（山东）大药厂有限公司4CYHS2404382马来酸曲美布汀片浙江诺得药业有限公司3CYHS2404381氯法齐明软胶囊Dong-A ST Co., Ltd.5.2JYHS2400065复方电解质醋酸钠注射液浙江高跖医药科技股份有限公司;浙江赛默制药有限公司3CYHS2404375氨酚羟考酮片北京华素制药股份有限公司3CYHS2404364托吡酯片山东新时代药业有限公司4CYHS2404366妥布霉素滴眼液江苏宝东医药科技有限公司;知和（山东）大药厂有限公4CYHS2404383盐酸头孢卡品酯颗粒苏州盛达药业有限公司;苏州第三制药厂有限责任公司4CYHS2404377阿托伐他汀钙片浙江江北药业有限公司4CYHS2404380阿仑膦酸钠口服溶液湖北欣泽霏药业有限公司3CYHS2404385恩格列净二甲双胍缓释片山东力诺制药有限公司;重庆博腾药业有限公司3CYHS2404373盐酸溴己新口服溶液湖北民康药业集团有限公司;南京海纳制药有限公司3CYHS2404367依折麦布阿托伐他汀钙片（Ⅱ）浙江昂利康制药股份有限公司4CYHS2404376盐酸溴己新口服溶液湖北民康药业集团有限公司;南京海纳制药有限公司3CYHS2404368 4、新增一致性评价补充申报药品名称企业名称受理号盐酸吡格列酮分散片双鹤天安药业（贵州）股份有限公司CYHB2450619地高辛片上海上药信谊药厂有限公司CYHB2450620甲硝唑片贵州百灵企业集团制药股份有限公司CYHB2450618头孢克肟胶囊海南日中天制药有限公司CYHB2450613地塞米松磷酸钠注射液广州白云山天心制药股份有限公司CYHB2450616法莫替丁注射液国药集团容生制药有限公司CYHB2450615阿司匹林肠溶片广东彼迪药业有限公司CYHB2450617头孢克肟胶囊海南日中天制药有限公司CYHB2450614 数据来源：摩熵医药用摩熵药筛小程序，随时随地查周报

一致性评价上市批准

2024-12-22

·信狐药迅

全球首个～只需每周一次皮下注射～先为达生物GLP-1新药提交上市申请|新受理（12.16-12.22）

本周药品注册受理数据，分门别类呈现，一目了然。(12.16-12.22）新药上市申请药品名称企业注册分类受理号伊诺格鲁肽注射液杭州先为达生物科技股份有限公司1CXSS2400141伊诺格鲁肽注射液杭州先为达生物科技股份有限公司1CXSS2400140 新药临床申请药品名称企业注册分类受理号JX2201胶囊浙江京新药业股份有限公司1CXHL2401428JX2201胶囊浙江京新药业股份有限公司1CXHL2401427JX2201胶囊浙江京新药业股份有限公司1CXHL2401426JX2201胶囊浙江京新药业股份有限公司1CXHL2401425LIT0922胶囊励缔(杭州)医药科技有限公司1CXHL2401420LIT0922胶囊励缔(杭州)医药科技有限公司1CXHL2401419FNX020片成都凡诺西生物医药科技有限公司1CXHL2401418FNX020片成都凡诺西生物医药科技有限公司1CXHL2401417POC101胶囊长春长乘医药科技有限公司1CXHL2401416POC101胶囊长春长乘医药科技有限公司1CXHL2401414GT919胶囊标新生物医药科技(上海)有限公司1CXHL2401411D-2570片益方生物科技(上海)股份有限公司1CXHL2401421GT919胶囊标新生物医药科技(上海)有限公司1CXHL2401412GT919胶囊标新生物医药科技(上海)有限公司1CXHL2401410WJ01024片苏州君境生物医药科技有限公司1CXHL2401407POC101胶囊长春长乘医药科技有限公司1CXHL2401415HC016脂质复合物注射液浙江海昶生物医药技术有限公司1CXHL2401413ABSK131胶囊上海和誉生物医药科技有限公司1CXHL2401406ABSK131胶囊上海和誉生物医药科技有限公司1CXHL2401405HTMC0658片上海壹典医药科技开发有限公司1CXHL2401404HTMC0658片上海壹典医药科技开发有限公司1CXHL2401403TT-00420片药捷安康(南京)科技股份有限公司1CXHL2401402TT-00420片药捷安康(南京)科技股份有限公司1CXHL2401401TT-00420片药捷安康(南京)科技股份有限公司1CXHL2401400注射用QD202上海魁特迪生物科技有限公司1CXHL2401393己二酸他雷替尼胶囊葆元生物医药科技(杭州)有限公司1CXHL2401392JYP0061片广州嘉越医药科技有限公司1CXHL2401387JYP0061片广州嘉越医药科技有限公司1CXHL2401386JYP0061片广州嘉越医药科技有限公司1CXHL2401385BIOT006片厦门宝太生物科技股份有限公司1CXHL2401397BIOT006片厦门宝太生物科技股份有限公司1CXHL2401396HW201877胶囊武汉人福创新药物研发中心有限公司1CXHL2401395HW201877胶囊武汉人福创新药物研发中心有限公司1CXHL2401394注射用LX22001山东罗欣药业集团股份有限公司2.1CXHL2401424注射用LX22001山东罗欣药业集团股份有限公司2.1CXHL2401423注射用BSY001北京北生研医药科技有限公司2.2CXHL2401422BCM235双释干混悬剂上海云晟研新生物科技有限公司2.2CXHL2401409BCM235双释干混悬剂上海云晟研新生物科技有限公司2.2CXHL2401408注射用BJ007上海宝济药业股份有限公司2.2CXHL2401399HY2233口服溶液浙江恒研医药科技有限公司2.2CXHL2401391吸入用H057上海汇伦医药股份有限公司2.2;2.4CXHL2401390盐酸艾司氯胺酮注射液宜昌人福药业有限责任公司2.4CXHL2401398恩那度司他片深圳信立泰药业股份有限公司2.4CXHL2401389恩那度司他片深圳信立泰药业股份有限公司2.4CXHL2401388注射用T320山西纳安生物科技股份有限公司1CXSL2400888PT886凡恩世制药(北京)有限公司1CXSL2400889OVV-01 注射液上海荣瑞医药科技有限公司1CXSL2400886同种异体脂肪间充质基质细胞注射液天士力医药集团股份有限公司1CXSL2400882OVV-01 注射液上海荣瑞医药科技有限公司1CXSL2400887IBI3007信达生物制药(苏州)有限公司1CXSL2400884注射用BR111浙江博锐生物制药有限公司1CXSL2400885FT-003注射液方拓生物科技(苏州)有限公司1CXSL2400883注射用PCNAT-01安达生物药物开发(深圳)有限公司1CXSL2400878MWN105注射液上海民为生物技术有限公司1CXSL2400879注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2400871注射用BGB-C354广州百济神州生物制药有限公司1CXSL2400877重组人源化抗表皮生长因子受体单抗注射液上海津曼特生物科技有限公司1CXSL2400876LP-003 注射液天辰生物医药(苏州)有限公司1CXSL2400875SYS6002石药集团巨石生物制药有限公司1CXSL2400873贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2400870阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2400872SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2400869 仿制药申请药品名称企业注册分类受理号复合磷酸氢钾注射液内蒙古白医制药股份有限公司3CYHS2404445维生素B6注射液江西远超医药科技有限公司3CYHS2404453碘[131I]化钠口服溶液广东君奇医药科技有限公司3CYHS2404438重酒石酸去甲肾上腺素注射液山西普恒制药有限公司3CYHS2404450尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404433尼莫地平口服溶液江苏联环药业股份有限公司3CYHS2404430盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司3CYHS2404429盐酸溴己新口服溶液河北汇德旭盛医药科技有限公司3CYHS2404428双氯芬酸依泊胺贴杭州端本医药科技有限公司3CYHS2404427注射用乳糖酸红霉素广东态森德制药有限公司3CYHS2404422盐酸赛庚啶口服溶液苏州华健瑞达医药技术有限公司3CYHS2404421重酒石酸去甲肾上腺素注射液浙江尚科生物医药有限公司3CYHS2404416硫酸镁注射液江苏润恒制药有限公司3CYHS2404413硫酸镁注射液江苏润恒制药有限公司3CYHS2404412倍他米松磷酸钠注射液河南利华制药有限公司3CYHS2404411头孢克肟颗粒广东华南药业集团有限公司3CYHS2404410布美他尼注射液云南华派医药科技有限公司3CYHS2404407环索奈德吸入气雾剂上海上药信谊药厂有限公司3CYHS2404405苯磺贝他斯汀口腔崩解片漯河市汇创医药有限公司3CYHS2404404吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司3CYHS2404418吸入用盐酸丙卡特罗溶液合肥国药诺和药业有限公司3CYHS2404417盐酸丙卡特罗颗粒四川大冢制药有限公司3CYHS2404400熊去氧胆酸片中山百灵生物技术股份有限公司3CYHS2404398苯磺酸氨氯地平口服溶液四川奥邦古得药业有限公司3CYHS2404396盐酸伐地那非口腔崩解片哈尔滨三联药业股份有限公司3CYHS2404392聚乙二醇4000散郑州泰丰制药有限公司3CYHS2404390盐酸布比卡因注射液湖北津药药业股份有限公司3CYHS2404387马来酸曲美布汀片浙江诺得药业有限公司3CYHS2404381复方电解质醋酸钠注射液浙江高跖医药科技股份有限公司3CYHS2404375恩格列净二甲双胍缓释片山东力诺制药有限公司3CYHS2404373恩格列净二甲双胍缓释片山东力诺制药有限公司3CYHS2404372硫代硫酸钠注射液赤峰源生药业有限公司3CYHS2404371肾上腺素注射液武汉久安药物研究院有限公司3CYHS2404369盐酸溴己新口服溶液湖北民康药业集团有限公司3CYHS2404368盐酸溴己新口服溶液湖北民康药业集团有限公司3CYHS2404367氨酚羟考酮片北京华素制药股份有限公司3CYHS2404364醋酸特利加压素注射液武汉华龙生物制药有限公司3CYHS2404363阿仑膦酸钠口服溶液湖北欣泽霏药业有限公司3CYHS2404385吸入用盐酸丙卡特罗溶液石家庄四药有限公司3CYHS2404384枸橼酸西地那非片广东培杰药物研究有限公司4CYHS2404446阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404444阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404443恩他卡朋双多巴片(II)浙江京新药业股份有限公司4CYHS2404442阿法骨化醇软胶囊南京海鲸药业股份有限公司4CYHS2404441盐酸伐昔洛韦片浙江车头制药股份有限公司4CYHS2404440注射用硫酸艾沙康唑湖南科伦制药有限公司4CYHS2404461玻璃酸钠滴眼液江苏福邦药业有限公司4CYHS2404460他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404459他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404458他达拉非片珠海联邦制药股份有限公司中山分公司4CYHS2404457比索洛尔氨氯地平片江苏德源药业股份有限公司4CYHS2404456甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404455甲磺酸沙非胺片南京正大天晴制药有限公司4CYHS2404454丁溴东莨菪碱注射液广东博卓医药科技有限公司4CYHS2404439依折麦布阿托伐他汀钙片(II)重庆圣华曦药业股份有限公司4CYHS2404452双氯芬酸钠肠溶片四川天德制药有限公司4CYHS2404451甲磺酸沙非胺片石家庄四药有限公司4CYHS2404435枸橼酸氢钾钠颗粒成都恒瑞制药有限公司4CYHS2404449枸橼酸西地那非片广东培杰药物研究有限公司4CYHS2404448枸橼酸西地那非片广东培杰药物研究有限公司4CYHS2404447注射用磷酸特地唑胺吉林津升制药有限公司4CYHS2404420甲磺酸沙非胺片石家庄四药有限公司4CYHS2404436盐酸尼卡地平注射液江西东抚制药有限公司4CYHS2404434甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404432甲磺酸沙非胺片四川科伦药业股份有限公司4CYHS2404431美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404426美阿沙坦钾片合肥立方制药股份有限公司4CYHS2404425盐酸氮斯汀滴眼液江西马应龙美康药业有限公司4CYHS2404424注射用氟氧头孢钠四川制药制剂有限公司4CYHS2404423卡泊三醇搽剂福元药业有限公司4CYHS2404415钆特醇注射液河北仁合益康药业有限公司4CYHS2404414富马酸伏诺拉生片重庆世森医药科技有限公司4CYHS2404409富马酸伏诺拉生片重庆世森医药科技有限公司4CYHS2404408非奈利酮片天地恒一制药股份有限公司4CYHS2404406比索洛尔氨氯地平片浙江百代医药科技有限公司4CYHS2404419盐酸奥洛他定滴眼液武汉新瑞医药科技有限公司4CYHS2404399硫酸羟氯喹片珠海润都制药股份有限公司4CYHS2404397培哚普利氨氯地平片(III)浙江华海药业股份有限公司4CYHS2404395格拉司琼透皮贴片杭州朱养心药业有限公司4CYHS2404393阿昔莫司胶囊河北锐健医药科技有限公司4CYHS2404391小儿法罗培南钠颗粒广东九明制药有限公司4CYHS2404389异氟烷福建海西联合药业有限公司4CYHS2404388夫西地酸乳膏西藏奥斯必秀医药有限公司4CYHS2404386阿贝西利片齐鲁制药有限公司4CYHS2404403阿贝西利片齐鲁制药有限公司4CYHS2404402阿贝西利片齐鲁制药有限公司4CYHS2404401盐酸尼卡地平注射液浙江花园药业有限公司4CYHS2404394氧(气态)河南心连心深冷能源股份有限公司4CYHS2404361氧(液态)河南心连心深冷能源股份有限公司4CYHS2404360妥布霉素滴眼液江苏宝东医药科技有限公司4CYHS2404383氧氟沙星滴耳液江苏宝东医药科技有限公司4CYHS2404382阿托伐他汀钙片浙江江北药业有限公司4CYHS2404380阿托伐他汀钙片浙江江北药业有限公司4CYHS2404379氢溴酸替格列汀片常州千红生化制药股份有限公司4CYHS2404378盐酸头孢卡品酯颗粒苏州盛达药业有限公司4CYHS2404377依折麦布阿托伐他汀钙片(II)浙江昂利康制药股份有限公司4CYHS2404376替米沙坦氨氯地平片江苏百佑药业有限公司4CYHS2404374夫西地酸乳膏广东科泓药业有限公司4CYHS2404370托吡酯片山东新时代药业有限公司4CYHS2404366托吡酯片山东新时代药业有限公司4CYHS2404365达格列净二甲双胍缓释片(I)南通联亚药业股份有限公司4CYHS2404362盐酸他喷他多口服溶液江苏恩华药业股份有限公司3CYHL2400265注射用甲磺酸萘莫司他湖南复瑞生物医药技术有限责任公司3CYHL2400262注射用甲磺酸萘莫司他湖南复瑞生物医药技术有限责任公司3CYHL2400261注射用甲磺酸萘莫司他山东化药医药科技有限公司3CYHL2400260洛索洛芬钠凝胶贴膏乐明药业(苏州)有限公司4CYHL2400266克霉唑阴道片浙江百代医药科技有限公司4CYHL2400264氟比洛芬凝胶贴膏乐明药业(苏州)有限公司4CYHL2400263水痘减毒活疫苗浙江天元生物药业有限公司3.3CXSL2400874Catumaxomab注射液(卡妥索单抗注射液)广州凌腾生物医药有限公司3.2CXSL2400880Catumaxomab注射液(卡妥索单抗注射液)广州凌腾生物医药有限公司3.2CXSL2400881 进口申请药品名称企业注册分类受理号氟替美维吸入粉雾剂GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND5.1JXHS2400116氟替美维吸入粉雾剂GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND5.1JXHS2400115盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2400114盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2400113伊曲莫德片EVEREST MEDICINES (SINGAPORE) PTE. LTD.5.1JXHS2400112布西珠单抗注射液Novartis Pharma Schweiz AG2.2JXSS2400112布西珠单抗注射液Novartis Pharma Schweiz AG2.2JXSS2400111氯法齐明软胶囊Dong-A ST Co., Ltd.5.2JYHS2400065PF-07220060Pfizer Inc.1JXHL2400299PF-07220060Pfizer Inc.1JXHL2400298PF-07220060Pfizer Inc.1JXHL2400297KFA115Novartis Pharma AG1JXHL2400295KFA115Novartis Pharma AG1JXHL2400294KFA115Novartis Pharma AG1JXHL2400293KFA115Novartis Pharma AG1JXHL2400292硫酸瑞美吉泮口崩片Pfizer Inc.2.4JXHL2400296AZD8630AstraZeneca AB1JXSL2400245AZD8630AstraZeneca AB1JXSL2400244AZD8630AstraZeneca AB1JXSL2400243DS-3939aDaiichi Sankyo, Inc.1JXSL2400242AZD4360AstraZeneca AB1JXSL2400241SAR402663注射液Sanofi-Aventis Recherche & Developpement1JXSL2400240Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1;2.2JXSL2400238Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1;2.2JXSL2400239 中药相关申请药品名称企业注册分类受理号仁术健胃颗粒南京中山制药有限公司1.1CXZS2400037小儿苓龙早熟颗粒盈科瑞(天津)创新医药研究有限公司1.1CXZL2400094散热止咳颗粒新奇康药业股份有限公司1.1CXZL2400091白头翁皂苷B4江西中医药大学1.2CXZL2400093白头翁皂苷B4栓江西中医药大学1.2CXZL2400092 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

2024-12-09

·investor.cumberlandpharma.com

FDA APPROVES ACETADOTE® sNDA

- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1. Acetaminophen, a common over-the-counter pain reliever and fever reducer, is the leading cause of acute liver failure in the United States. Each year, thousands of individuals experience accidental or intentional acetaminophen poisoning, leading to serious liver damage. The newly approved dosing regimen simplifies the administration of Acetadote by combining the first two bags of the standard regimen into a single, slower infusion. This streamlined approach has been implemented in hospitals across multiple countries and demonstrated to reduce the frequency of medication errors and potentially serious non-allergic anaphylactoid reactions (NAARs) without compromising the effectiveness of Acetadote2-6. By simplifying the dosing regimen, health care providers can administer the life-saving treatment more efficiently, potentially improving patient outcomes. "This FDA approval is a significant step forward in the treatment of acetaminophen overdose," said Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and Drug Center. "By streamlining the administration of NAC, we can improve patient outcomes and reduce the risk of adverse events. This simplified dosing regimen is a valuable tool for health care providers in managing this potentially life-threatening condition." "We are thrilled to announce the FDA approval of this simplified dosing regimen for Acetadote," said A.J. Kazimi, Cumberland's Chief Executive Officer. "This important milestone underscores our commitment to improving patient care and providing innovative solutions for urgent medical needs. By streamlining the administration process, we aim to enhance patient outcomes and reduce the burden on health care providers." Key Highlights: FDA-approved sNDA adds a simplified, IV NAC dosing regimen to the product prescribing information. New IV NAC dosing regimen is both safe and effective. New dosing regimen aims to minimize interruptions in care, medication errors and incidence of dose-related reactions. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website www.cumberlandpharma.com. References: Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-acetadote-snda-302326652.html SOURCE Cumberland Pharmaceuticals Inc. Investor Contact: Shayla Simpson, Cumberland Pharmaceuticals, (615) 255-0068; Media Contact: Molly Aggas, Dalton Agency, (704) 641-6641

上市批准临床2期

100 项与格拉司琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04370	格拉司琼	A04AA02	DB00889

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
化疗引起的恶心和呕吐	列支敦士登	Grünenthal GmbH	2012-04-20
化疗引起的恶心和呕吐	冰岛	Grünenthal GmbH	2012-04-20
化疗引起的恶心和呕吐	挪威	Grünenthal GmbH	2012-04-20
化疗引起的恶心和呕吐	欧盟	Grünenthal GmbH	2012-04-20
恶心	中国	福安药业（集团）股份有限公司	-
术后恶心呕吐	中国	福安药业（集团）股份有限公司	-
呕吐	中国	福安药业（集团）股份有限公司	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶心	药物发现	中国	依格斯（北京）医疗科技有限公司	2013-08-28
恶心	药物发现	中国	Strakan International Ltd.	2013-08-28
恶心	药物发现	中国	Aveva Drug Delivery Systems, Inc.	2013-08-28
肿瘤	药物发现	中国	Aveva Drug Delivery Systems, Inc.	2013-08-28
呕吐	药物发现	中国	Strakan International Ltd.	2013-08-28
呕吐	药物发现	中国	依格斯（北京）医疗科技有限公司	2013-08-28
呕吐	药物发现	中国	Aveva Drug Delivery Systems, Inc.	2013-08-28
恶心和呕吐	药物发现	美国	Heron Therapeutics, Inc.	2006-06-01
实体瘤	药物发现	美国	Heron Therapeutics, Inc.	2006-06-01
化疗引起的恶心和呕吐	药物发现	-	Kyowa Kirin Co., Ltd.	2006-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


JPRN-jRCTs031180378 (WCLC2021)	临床2期	恶心和呕吐	25	Oral Granisetron	觸窪觸齋範鏇鹹蓋憲夢(鬱網構遞廠遞艱鏇製衊) = 願齋網醖襯範鹹遞築製鏇鹹糧遞獵襯鑰選憲鬱 (製餘鏇築觸觸艱醖遞餘, 59.3 ~ 93.2) 更多	-	2021-09-08
ASCO2021	N/A	化疗引起的恶心和呕吐	-	Granisetron extended-release subcutaneous injection (GERSC)	網遞獵鬱構鹹鑰鏇鹽簾(遞鹹醖膚壓齋鏇糧鏇廠) = 窪壓願糧簾膚膚餘觸積糧餘襯艱醖餘餘艱選積 (觸艱選簾淵範糧廠製膚 ) 更多	-	2021-05-28
				Palonosetron (PALO)	網遞獵鬱構鹹鑰鏇鹽簾(遞鹹醖膚壓齋鏇糧鏇廠) = 糧艱夢鏇觸淵憲餘膚遞糧餘襯艱醖餘餘艱選積 (觸艱選簾淵範糧廠製膚 ) 更多
NCT01989221 (CTgov)	临床3期	恶心 \| 胃轻瘫 \| 呕吐	14	Sancuso®	膚遞艱窪淵觸齋製襯廠(鏇襯選廠繭鏇簾範築鬱) = 夢夢鑰願築製夢選鏇艱繭廠壓廠積鹹衊蓋糧膚 (廠鬱艱觸網憲鬱鏇鬱鏇, 範網膚積艱壓網窪觸鬱 ~ 鑰鬱糧鏇鹹製繭繭鬱蓋) 更多	-	2021-05-26
NCT01536392 (CTgov)	临床3期	宫颈癌	76	Granisetron (Arm 1: Transdermal Granisetron)	餘選醖積憲糧鬱糧糧淵(築遞範鹽遞構淵願壓獵) = 選獵繭鬱築選淵夢窪鹹鏇顧夢顧遞餘窪齋鏇糧 (鹹壓遞積繭繭膚襯壓憲, 齋膚衊鹽願淵醖範窪觸 ~ 餘襯顧膚壓夢膚積積繭) 更多	-	2021-05-17
				Ondansetron (Arm 2: Oral Ondansetron)	餘選醖積憲糧鬱糧糧淵(築遞範鹽遞構淵願壓獵) = 鬱觸衊醖襯鑰選顧襯鹹鏇顧夢顧遞餘窪齋鏇糧 (鹹壓遞積繭繭膚襯壓憲, 淵網廠獵選範鏇網選鬱 ~ 淵製艱齋醖壓繭顧夢夢) 更多
NCT03503292 (CTgov)	临床4期	恶心 \| 术后恶心呕吐	92	Granisetron (CYP2D6 Rapid Metabolizer (Granisetron))	繭襯廠膚願製範積鏇鹹(憲鏇構鬱窪網鑰窪憲獵) = 鬱觸觸窪簾齋醖鹽願製窪衊遞積鏇顧醖繭襯襯 (廠夢夢膚顧夢齋製醖膚, 窪構選觸顧糧窪醖壓襯 ~ 構齋簾築築鏇顧鬱構糧) 更多	-	2020-10-28
				Ondansetron (CYP2D6 Normal Metabolizer (Ondansetron))	繭襯廠膚願製範積鏇鹹(憲鏇構鬱窪網鑰窪憲獵) = 鑰齋醖鑰鑰繭衊憲觸願窪衊遞積鏇顧醖繭襯襯 (廠夢夢膚顧夢齋製醖膚, 醖夢壓夢廠選製蓋齋淵 ~ 艱願膚願鹹蓋遞構選夢) 更多
NCT02457195 (GTPPONV, CTgov)	临床2期	术后恶心呕吐 \| 呕吐	50	granisetron	範鑰廠選網襯憲膚繭鹹(範窪鑰鑰醖淵獵鑰遞廠) = 簾願窪築選簾淵鏇憲廠醖繭壓餘獵築範範淵簾 (顧鬱膚鏇簾願齋製鹹鹽, 齋鬱網網範積繭鑰鬱願 ~ 範衊遞鬱齋觸製鏇廠鑰) 更多	-	2019-04-16
ESMO2018	N/A	乳腺癌	118	Palonosetron 0.25mg	(簾製淵廠壓遞憲鑰鏇窪) = 鹹鏇積鹽積夢襯壓願製壓簾願壓鏇廠遞構選網 (糧鹽糧廠衊鬱餘獵鏇鑰 ) 更多	-	2018-10-22
				Granisetron 3mg	(簾製淵廠壓遞憲鑰鏇窪) = 餘鹽繭餘積築醖構鹽淵壓簾願壓鏇廠遞構選網 (糧鹽糧廠衊鬱餘獵鏇鑰 ) 更多
NCT01275664 (CTgov)	N/A	恶心 \| 恶心和呕吐 \| 原发性腹膜癌 \| 卵巢混合上皮癌 \| 浆液性囊腺癌 \| 粘液性囊腺癌 \| 未分化卵巢癌 \| 卵巢子宫内膜样癌 \| Brenner瘤 \| 呕吐 \| 输卵管癌	4	Adjuvant Therapy+Granisetron Transdermal Patch+Carboplatin+cisplatin+Aprepitant+Dexamethasone	夢鑰築糧襯鏇廠醖鏇願(憲繭觸壓壓夢繭鹹膚襯) = 鹽遞餘製選積膚獵醖餘構繭憲醖齋鑰鏇糧醖簾 (壓選簾願襯艱範醖壓觸, 艱製遞廠選襯築網製壓 ~ 積鏇鹽憲鹹醖憲襯顧鬱) 更多	-	2018-04-12
NCT00186628 (CTgov)	临床2期	套细胞淋巴瘤 \| 慢性移植物抗宿主病 \| 肥大细胞白血病	36	Anti-thymoglobulin, rabbit (ATG, rabbit ATG)+Granisetron+Solumedrol+Cyclosporine+Acetaminophen+Filgrastim+Hydrocortisone+Mycophenylate mofetil+Diphenhydramine+Rituximab	鏇遞築遞獵淵襯夢鏇鏇(鹹餘鏇選鬱觸鹽鏇獵觸) = 鏇築壓餘顧遞繭膚鬱鏇醖膚築齋範壓糧衊積襯 (構鏇選壓襯衊衊壓製夢, 鏇鏇簾鬱願繭簾壓醖繭 ~ 選繭鬱範衊壓廠糧範網) 更多	-	2017-11-28
NCT02106494 (Pubmed \| Cancer Manag Res) 人工标引	临床3期	恶心 \| 呕吐	589	fosaprepitant+dexamethasone+APF530	(獵構繭餘範遞醖衊窪築) = 鏇鬱鏇糧願淵衊簾築醖淵繭夢鏇糧積壓顧膚襯 (壓簾廠繭醖襯積壓壓夢 )	优效	2017-05-19
				fosaprepitant+dexamethasone+ondansetron	(獵構繭餘範遞醖衊窪築) = 製憲艱淵窪觸膚襯鑰淵淵繭夢鏇糧積壓顧膚襯 (壓簾廠繭醖襯積壓壓夢 )